Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated 6 enrolled GlaxoSmithKline Merck Sharp & Dohme LLC · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.

Timeline

Start: 2017-08-18
Primary completion: 2020-07-13
Completion: 2020-11-05

Outcome

Outcome not reported

Stopped (Business): “The study was terminated following an internal review of the company's research and development portfolio”

Publications

Nishihori T, Hoffman JE, Huff A, Kapoor GS, Eleftheriadou I, Zajic S, Urbano A, Suchindran S, Chisamore M, D'Souza JW, Faitg T, Rapoport AP. Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma. Blood Adv. 2023 Apr 11;7(7):1168-1177. doi: 10.1182/bloodadvances.2022008460.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Letetresgene autoleucel	Cell therapy	—	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	Intravenous
Background	Fludarabine	Small molecule	—	Intravenous